ProMetic Life Sciences has entered into a strategic agreement with Omino, which exclusively provides ProMetic with a competitive intellectual property position as well as a comprehensive proprietary understanding of the use of plasminogen in the field of hard-to-treat wounds.
Under the agreement, ProMetic has secured exclusive license rights to both issues and pending patents for the use of plasminogen related to wound healing. The agreement also provides the company access to extensive preclinical data as well as unique proof-of-concept efficacy data in patients.
Hard-to-treat wounds such as diabetic foot ulcers affect millions of patients in the United States alone and represent annual incremental healthcare costs as high as $12 billion. Studies have indicated that diabetics have a lifetime risk as high as 25 per cent of developing foot ulcers and annual incident cases are cite to range from 3 to 10 per cent.
Pierre Laurin, president and CEO of ProMetic, said: “Dr. Ny and his esteemed colleagues at Omnio have decades of hands-on experience demonstrating the ability of plasminogen to accelerate the healing of otherwise very hard-to-treat wounds. Combining their unique knowhow with our own clinical experience from our ongoing US plasminogen clinical trial bodes very well for improving the future management of diabetic wounds.”
The agreement also provides for the creation of a centre of excellence in Umea, Sweden to capitalise on the experience of Dr Tor Ny, founder of Omnio AB and Professors at the University of Umea.
The financial terms of his agreement were not disclosed.